Daewoong pharmaceutical Co.,Ltd (069620.KS)
KRW 125500.0
(-2.64%)
KRW 125500.0
(-2.64%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 133.4 Billion KRW | 112.12% |
| 2022 | 57.09 Billion KRW | 106.84% |
| 2021 | 27.6 Billion KRW | 62.58% |
| 2020 | 16.97 Billion KRW | -62.0% |
| 2019 | 44.68 Billion KRW | 81.91% |
| 2018 | 24.56 Billion KRW | -36.94% |
| 2017 | 38.95 Billion KRW | 50.45% |
| 2016 | 25.89 Billion KRW | -40.56% |
| 2015 | 43.56 Billion KRW | -16.13% |
| 2014 | 51.94 Billion KRW | -27.22% |
| 2013 | 71.37 Billion KRW | 93.51% |
| 2012 | 36.88 Billion KRW | -42.04% |
| 2011 | 63.63 Billion KRW | -10.68% |
| 2010 | 71.23 Billion KRW | -4.64% |
| 2009 | 74.7 Billion KRW | 77.94% |
| 2008 | 41.98 Billion KRW | -42.81% |
| 2007 | 73.39 Billion KRW | 4.43% |
| 2006 | 70.28 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 29.66 Billion KRW | 3.41% |
| 2024 Q2 | 42.31 Billion KRW | 42.66% |
| 2023 FY | 121.11 Billion KRW | 112.12% |
| 2023 Q1 | 24.47 Billion KRW | 93.96% |
| 2023 Q4 | 28.68 Billion KRW | -2.38% |
| 2023 Q3 | 29.38 Billion KRW | -26.65% |
| 2023 Q2 | 40.05 Billion KRW | 63.67% |
| 2022 Q3 | 30.09 Billion KRW | 0.22% |
| 2022 Q4 | 12.61 Billion KRW | -58.08% |
| 2022 FY | 57.09 Billion KRW | 106.84% |
| 2022 Q2 | 30.03 Billion KRW | 30.3% |
| 2022 Q1 | 23.04 Billion KRW | -7.55% |
| 2021 Q3 | 22.71 Billion KRW | 21.45% |
| 2021 Q1 | 22.55 Billion KRW | 158.73% |
| 2021 Q2 | 18.7 Billion KRW | -17.09% |
| 2021 Q4 | 24.93 Billion KRW | 9.77% |
| 2021 FY | 27.6 Billion KRW | 62.58% |
| 2020 Q4 | 8.71 Billion KRW | 47.28% |
| 2020 Q1 | 5.56 Billion KRW | 79.65% |
| 2020 FY | 16.97 Billion KRW | -62.0% |
| 2020 Q3 | 5.91 Billion KRW | 283.49% |
| 2020 Q2 | -3.22 Billion KRW | -157.94% |
| 2019 FY | 44.68 Billion KRW | 81.91% |
| 2019 Q1 | 12.62 Billion KRW | 267.04% |
| 2019 Q3 | 6.21 Billion KRW | -72.7% |
| 2019 Q4 | 3.09 Billion KRW | -50.1% |
| 2019 Q2 | 22.74 Billion KRW | 80.12% |
| 2018 Q3 | 7.19 Billion KRW | -16.01% |
| 2018 FY | 24.56 Billion KRW | -36.94% |
| 2018 Q1 | 5.35 Billion KRW | -36.32% |
| 2018 Q2 | 8.57 Billion KRW | 59.98% |
| 2018 Q4 | 3.44 Billion KRW | -52.2% |
| 2017 Q1 | 5.88 Billion KRW | -47.3% |
| 2017 FY | 38.95 Billion KRW | 50.45% |
| 2017 Q4 | 8.41 Billion KRW | -37.96% |
| 2017 Q3 | 13.56 Billion KRW | 22.24% |
| 2017 Q2 | 11.09 Billion KRW | 88.36% |
| 2016 FY | 25.89 Billion KRW | -40.56% |
| 2016 Q1 | 4.39 Billion KRW | 29.59% |
| 2016 Q4 | 11.17 Billion KRW | 137.85% |
| 2016 Q3 | 4.69 Billion KRW | -16.5% |
| 2016 Q2 | 5.62 Billion KRW | 28.06% |
| 2015 FY | 43.56 Billion KRW | -16.13% |
| 2015 Q1 | 13.12 Billion KRW | 175.05% |
| 2015 Q2 | 16.24 Billion KRW | 23.73% |
| 2015 Q3 | 10.8 Billion KRW | -33.47% |
| 2015 Q4 | 3.39 Billion KRW | -68.62% |
| 2014 Q1 | 14.5 Billion KRW | 66.18% |
| 2014 FY | 51.94 Billion KRW | -27.22% |
| 2014 Q3 | 15.14 Billion KRW | -13.54% |
| 2014 Q4 | 4.77 Billion KRW | -68.49% |
| 2014 Q2 | 17.52 Billion KRW | 20.8% |
| 2013 Q2 | 21.57 Billion KRW | 32.32% |
| 2013 Q1 | 16.3 Billion KRW | 48.89% |
| 2013 FY | 71.37 Billion KRW | 93.51% |
| 2013 Q4 | 8.72 Billion KRW | -64.84% |
| 2013 Q3 | 24.82 Billion KRW | 15.06% |
| 2012 FY | 36.88 Billion KRW | -42.04% |
| 2012 Q1 | 12.63 Billion KRW | 0.0% |
| 2012 Q2 | 132.84 Million KRW | -98.95% |
| 2012 Q3 | 14.76 Billion KRW | 11013.64% |
| 2012 Q4 | 10.95 Billion KRW | -25.81% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 63.63 Billion KRW | -10.68% |
| 2011 Q3 | 22.82 Billion KRW | 5.06% |
| 2011 Q2 | 21.72 Billion KRW | 16.09% |
| 2011 Q1 | 18.71 Billion KRW | 0.0% |
| 2010 Q2 | 31.03 Billion KRW | 39.94% |
| 2010 FY | 71.23 Billion KRW | -4.64% |
| 2010 Q3 | 24.24 Billion KRW | -21.88% |
| 2010 Q1 | 22.17 Billion KRW | -4.26% |
| 2009 Q4 | 23.16 Billion KRW | 30.61% |
| 2009 FY | 74.7 Billion KRW | 77.94% |
| 2009 Q3 | 17.73 Billion KRW | 52.86% |
| 2009 Q2 | 11.6 Billion KRW | 0.0% |
| 2009 Q1 | - KRW | -100.0% |
| 2008 FY | 41.98 Billion KRW | -42.81% |
| 2008 Q3 | 14.92 Billion KRW | -8.06% |
| 2008 Q1 | - KRW | -100.0% |
| 2008 Q2 | 16.23 Billion KRW | 0.0% |
| 2008 Q4 | 8.08 Billion KRW | -45.85% |
| 2007 Q2 | 17 Billion KRW | 0.0% |
| 2007 FY | 73.39 Billion KRW | 4.43% |
| 2007 Q4 | 20.4 Billion KRW | -6.28% |
| 2007 Q3 | 21.77 Billion KRW | 28.1% |
| 2006 FY | 70.28 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -36496.206% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | -73.522% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 267.677% |
| HANDOK Inc. | 12.57 Billion KRW | -960.565% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 6806.745% |
| Yuhan Corporation | 74.56 Billion KRW | -78.919% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -1093.427% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 839.402% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 40.678% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -4265.319% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -829.637% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -22268.566% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -13742.244% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -393.524% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -36496.206% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 1820.034% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -3207.362% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 290.716% |
| JW Holdings Corporation | 143.66 Billion KRW | 7.141% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 349.743% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 45.901% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | -33.003% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 381.494% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -1825.915% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -1961.601% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -1427.9% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -36496.206% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | -173.556% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | -33.003% |
| Yuhan Corporation | 74.56 Billion KRW | -78.919% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -537.694% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -4179.431% |
| Suheung Co., Ltd. | 42.99 Billion KRW | -210.285% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | -33.003% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -551.262% |
| Korea United Pharm Inc. | 54.94 Billion KRW | -142.78% |
| CKD Bio Corp. | -20.15 Billion KRW | 761.985% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | -313.885% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -427.256% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | -310.166% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 381.494% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | -302.472% |
| Boryung Corporation | 68.26 Billion KRW | -95.419% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 455.782% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -829.637% |
| JW Lifescience Corporation | 32.09 Billion KRW | -315.708% |